###### Significance of this study

What is already known on this subject?
======================================

-   Overactivation of Wnt/β-catenin signalling through *APC* or *CTNNB1* mutation underlies the majority of colorectal cancer cases.

-   A subset of human colon tumours harbour gene fusions of *RSPO2* or *RSPO3*, associated with enhanced expression of these genes.

-   R-spondin proteins promote Wnt/β-catenin signalling.

-   Inhibition of RSPO3 reduces the growth of existing *RSPO3*-fusion-positive tumours in xenograft models.

What are the new findings?
==========================

-   *Rspo3* expression causes rapid development of adenoma and adenocarcinoma in the intestine, establishing RSPO3 as an efficient, causal driver of intestinal cancer. RSPO3 drives extensive crypt hyperplasia and expands multiple crypt components, including Lgr5^+^ stem cells, Paneth cells, non-Paneth cell label-retaining cells and Lgr4^+^ cells.

-   The robust RSPO3-induced phenotype is associated with a modest increase in Wnt/β-catenin signalling.

How might it impact on clinical practice in the foreseeable future?
===================================================================

-   The potency of RSPO3 to stimulate the crypt stem cells and niche cells, and to actively drive tumorigenesis, proposes RSPO3 as a useful candidate target for therapy in patients with colorectal cancer harbouring *RSPO3* fusions.

Introduction {#s1}
============

Although in the majority of colorectal cancer cases the Wnt/β-catenin pathway is deregulated through mutations in adenomatous polyposis coli (*APC)* or β-catenin (*CTNNB1),* two studies reported gene fusions of the R-spondin family members *RSPO2* and *RSPO3* in a subset of human colon tumours, accompanied by enhanced expression of these genes.[@R1] [@R2] R-spondins are secreted proteins that potentiate Wnt/β-catenin signalling following binding of the leucine-rich repeat-containing G-protein coupled receptors (LGR), in the intestine represented by LGR5 and LGR4. Whereas LGR5 predominantly marks the cycling stem cells at the crypt bottom that fuel the continuous renewal of the intestinal epithelium, LGR4 is present throughout the entire crypt, on cycling stem cells, transient amplifying cells and Paneth cells.[@R3] [@R4] Paneth cells fulfil a crucial role in the intestinal crypts by providing the stem cells with a supporting niche.[@R5] In addition to the cycling stem cells, a pool of more quiescent +4 stem cells has been identified that coexpress *Lgr5* and Paneth cell markers.[@R6] These label-retaining cells (LRCs) serve as Paneth cell precursors and as 'reserve' stem cells, able to acquire cycling capacities upon damage.[@R7] [@R8]

*RSPO2* and *RSPO3* fusions are mutually exclusive with *APC* and *CTNNB1* mutations in human colon tumours, suggesting that a gain in RSPO can substitute for these most common mutations as an alternative driver of intestinal tumorigenesis.[@R1] Moreover, all the *RSPO*-fusion-positive colon tumours were described to harbour a mutation in either *KRAS* or *BRAF*, mutations that often co-occur in *APC* mutant settings as well.[@R1] Involvement of RSPO3 in growth of pre-existing tumours was recently shown in *RSPO3*-fusion-positive xenograft models, where anti-RSPO3 treatment inhibited tumour growth.[@R9] [@R10] Whether indeed solely a gain in RSPO3 has the potency to act as a causal driver of intestinal cancer remained to be determined. Here, we demonstrate that RSPO3 is an oncogenic driver, rapidly causing intestinal cancer and extensive crypt hyperplasia, concomitantly stimulating stem cells and supportive niche cells.

Results {#s2}
=======

*Rspo3* expression induces extensive intestinal hyperplasia and tumorigenesis {#s2a}
-----------------------------------------------------------------------------

To investigate the in vivo consequence of a gain in RSPO3, we generated a conditional *Rspo3* transgenic mouse model. The used *Rspo3* transgene was verified to encode secreted and biologically active RSPO3 protein using β-catenin luciferase reporter assays (see online [supplementary figure](#SM1){ref-type="supplementary-material"} S1A). In generating the mouse model, the *Rspo3* coding sequence was inserted in the inverse orientation, flanked by two pairs of oppositely oriented, homologous *Lox* sites and behind the ubiquitous CAGGS promoter ([figure 1](#GUTJNL2016311606F1){ref-type="fig"} and see online [supplementary figure](#SM1){ref-type="supplementary-material"} S1B). This design enables conditional *Rspo3* expression upon Cre activity. Cre was provided by crossing our *Rspo3inv*^f/+^ (Rspo3^inv^) mice to *Lgr5*-GFP-Cre^ERT2^ (Lgr5) mice[@R11] and activation of the inducible Cre^ERT2^ recombinase was achieved by tamoxifen injection at the age of 2 months, unless mentioned otherwise. Single transgenic Lgr5 and Rspo3^inv^ animals served as controls and were treated identically as double transgenic Lgr5;Rspo3 mice. Efficient expression of sense-oriented transgenic *Rspo3* upon tamoxifen injection was confirmed in double transgenic Lgr5;Rspo3 animals exclusively and throughout the small and large intestine (see online [supplementary figure](#SM1){ref-type="supplementary-material"} S1D). Correspondingly, we confirmed RSPO3 protein expression, observed in double transgenic mice only (see online [supplementary figure](#SM1){ref-type="supplementary-material"} S1E).

![Simplified schematic representation of the *Rspo3*^inv^ mouse model. The *Rspo3* coding sequence is inserted in the inverse orientation between two pairs of oppositely oriented *Lox* sites and behind the CAGGS promoter. Cre activity causes inversion of the *Rspo3* transgene into the sense orientation using either one of the homologous *LoxP* or *Lox511* pairs, leading to the middle two transgenic *Rspo3* products. Subsequent excision of the remaining sequences in between the homologous *Lox* sites that are now in the same direction provides a product with sense oriented, irreversible *Rspo3* expression. Both intermediate and locked *Rspo3* recombination products encode *Rspo3* sense mRNA.](gutjnl-2016-311606f01){#GUTJNL2016311606F1}
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Transgenic *Rspo3* expression caused abdominal enlargement and often led to rectum prolapses in double transgenic animals within several weeks, urging their analysis mostly within 2 months following induction. The intestines of Lgr5;Rspo3 mice appeared elongated and distended, and microscopic analysis revealed mucosal thickening caused by extensive epithelial hyperplasia ([figure 2](#GUTJNL2016311606F2){ref-type="fig"}A, B). This robust phenotype was observed exclusively though in all double transgenic animals. Hyperplastic lesions extended upwards from crypts to the lumen, integrating with pre-existing villi and appearing as multiple microadenomatous nodules, typically showing dislocated Paneth cells and high rates of mitosis and local necrotic changes ([figure 2](#GUTJNL2016311606F2){ref-type="fig"}B, C). These lesions were observed throughout the entire small intestine, in the caecum and proximal colon (see online [supplementary figure](#SM1){ref-type="supplementary-material"} S2A). In addition, the majority of animals developed adenomas ([figure 2](#GUTJNL2016311606F2){ref-type="fig"}D), some of which even progressed to adenocarcinomas as indicated by local invasion ([figure 2](#GUTJNL2016311606F2){ref-type="fig"}E). On average 2.5 (±2.3) tumours, mostly adenomas, were detected per Lgr5;Rspo3 mouse, most of which developed in the jejunum, ileum and caecum ([figure 2](#GUTJNL2016311606F2){ref-type="fig"}F, G). When tamoxifen was injected at 25 days of age, the phenotype and tumour incidence (average 2.6±2.4, see online [supplementary figure](#SM1){ref-type="supplementary-material"} S2B) were comparable to that of mice injected at 2 months of age. These data provide evidence that *Rspo3* drives rapid intestinal tumorigenesis and extensive hyperplastic growth.

![*Rspo3* induces extensive intestinal hyperplasia and tumorigenesis. H&E stainings of small intestine of (A) Rspo3^inv^ control and (B-E) Lgr5;Rspo3 mice, including representative examples of (C) hyperplastic, (D) adenomatous and (E) adenocarcinomatous growth, (C--E) lower panels showing an enlargement of the boxed regions. (F) Tumour occurrence in Lgr5;Rspo3 animals (n=16) as illustrated by (F) the amount of tumours per mouse, lines indicating the median, and (G) tumour distribution (percentage of tumours detected per region).](gutjnl-2016-311606f02){#GUTJNL2016311606F2}

RSPO3 expands Lgr5^+^ stem cells and Paneth cells {#s2b}
-------------------------------------------------

We examined the occurrence of crypt cells by staining for green fluorescent protein (GFP) representing *Lgr5-*GFP-Cre^ERT2^ expressing cells and lysozyme indicating Paneth cells. In Lgr5 control mice, we observed GFP expression specifically in the crypt bottom stem cells and in a stochastic fashion, as has been reported ([figure 3](#GUTJNL2016311606F3){ref-type="fig"}A upper panel).[@R11] In the intestines of Lgr5;Rspo3 animals, we noticed an expansion of the Lgr5-GFP^+^ stem cell zone in hyperplastic and neoplastic lesions ([figure 3](#GUTJNL2016311606F3){ref-type="fig"}A). In parallel, we observed a clear increase in the abundance of Paneth cells in the *Rspo3*-induced lesions in Lgr5;Rspo3 mice ([figure 3](#GUTJNL2016311606F3){ref-type="fig"}B). Paneth cells were dislocated, presenting higher upwards towards the lumen, reaching higher up than the Lgr5^+^ cells. More specifically in adenoma, Paneth cells were observed dispersed throughout the entire tumour, whereas Lgr5-positive cells were present mainly in the lower parts of these lesions. Notably, Paneth cells were prominently present at the invading front of adenocarcinomatous lesions, as were Lgr5^+^ cells though less consistent. Even in the proximal large intestine, RSPO3 induced the appearance of lysozyme-positive Paneth cells, which are normally absent in the mouse large intestine ([figure 3](#GUTJNL2016311606F3){ref-type="fig"}C). In accordance with the abnormal growth and crypt expansion observed in *Rspo3* expressing mice, proliferation was clearly enhanced, as well as the amount of Sox9-positive cells ([figure 4](#GUTJNL2016311606F4){ref-type="fig"}A, B). Nuclear β-catenin was detected in some Paneth cells though appeared hardly affected by transgenic *Rspo3* expression ([figure 4](#GUTJNL2016311606F4){ref-type="fig"}C), suggesting a relatively moderate gain in Wnt/β-catenin signalling in our Lgr5;Rspo3 model compared with *Apc* mutant mouse models. Indeed, we did detect clear nuclear β-catenin in tumours of age-matched and background-matched *Apc*^Min^ mice (see online [supplementary figure](#SM1){ref-type="supplementary-material"} S3A). Taken together, RSPO3 imposes hyperplastic, adenomatous and adenocarcinomatous growth in the mouse intestine, accompanied by expansion of the crypt compartment, including Lgr5^+^ stem cells, Paneth cells and proliferative progenitor cells.

![Rspo3 induces expansion of Lgr5 stem cells and Paneth cells. Immunohistochemical staining of (A) GFP and (B) lysozyme in representative hyperplastic and neoplastic lesions in the small intestine. (C) Lysozyme staining showing Paneth cell metaplasia in hyperplastic proximal colon (middle panel) and in adenoma at the caecum-colon transition (lower panel).](gutjnl-2016-311606f03){#GUTJNL2016311606F3}

![*Rspo3-*induced lesions are highly proliferative. Immunohistochemical staining of (A) Ki67, (B) Sox9 and (C) β-catenin in representative *Rspo3*-induced lesions. Inserts show predominant membranous β-catenin expression besides mild nuclear detection in Paneth cells.](gutjnl-2016-311606f04){#GUTJNL2016311606F4}

RSPO3 causes expansion of additional crypt cell types {#s2c}
-----------------------------------------------------

In the setting of *Apc* deletion in Lgr5 cells, Lgr5^+^ stem cells have been reported as the cells of origin in the developing adenoma.[@R12] [@R13] We performed lineage tracing experiments to examine a possible Lgr5^+^ stem cell derivation of the *Rspo3-*induced lesions. Lgr5;Rspo3 mice were cross-bred to mTmG Cre reporter mice, enabling detection of an intense GFP signal in the progeny upon Cre-mediated switching, well distinguishable from the weaker GFP staining derived from the *Lgr5*-GFP-Cre^ERT2^ cassette. In Lgr5;mTmG mice without transgenic *Rspo3*, ribbons of GFP^hi^ staining presented from the crypts upwards into the villi ([figure 5](#GUTJNL2016311606F5){ref-type="fig"}A). However, upon *Rspo3* expression the overall occurrence of GFP^hi^ cells seemed reduced, appearing less frequent and only in small foci, leaving the vast majority of the *Rspo3*-induced hyperplasias and tumours untraced ([figure 5](#GUTJNL2016311606F5){ref-type="fig"}A). A similar reduction in lineage tracing was observed upon *Rspo3* expression using Rosa26-LacZ mice as a Cre reporter ([figure 5](#GUTJNL2016311606F5){ref-type="fig"}B). Although stochastic expression and suboptimal efficiency of Cre could cause under-representation of Lgr5-derived lineage tracing, this holds true both for mice expressing as well as lacking transgenic *Rspo3*, and thus cannot explain the relative reduction in *Lgr5*-Cre-driven lineage tracing in *Rspo3* expressing mice. This indicates that Lgr5^+^ cells are not the sole cells of origin and alternative cell types must be involved in the development of the *Rspo3*-driven lesions.

![*Rspo3* expands additional crypt cell types. (A) GFP immunostaining in the small intestine of Lgr5;mTmG mice with or without transgenic *Rspo3.* GFP^high^ cells indicate mTmG reporter activity, distinguishable from GFP^mid^ cells derived from the *Lgr5*-GFP-Cre^ERT2^ cassette. (B) X-gal staining of Lgr5;R26-LacZ mice with or without transgenic *Rspo3*. In situ hybridisation showing *Lgr4* and *Lgr5* mRNA expression (C) in an *Rspo3-*induced adenoma of an Lgr5;Rspo3 mouse and (D) in a xenograft of a human *RSPO3*-fusion-positive colon tumour. (E) Representative example of bromodeoxyuridine (BrDU)-lysozyme double immunostaining in Lgr5 single and Lgr5;Rspo3 double transgenic jejunum, 2 weeks after repetitive BrDU injections. Arrows indicate lysozyme-positive label-retaining cells (LRCs) (black) and lysozyme-negative LRCs (grey). (F) Quantification of BrDU-retaining cells in the jejunum, being either lysozyme-negative or lysozyme-positive (2 weeks after BrDU), showing averages and SDs over three independent experiments. \*p\<0.05, \*\*p\<0.01, Student\'s t-test.](gutjnl-2016-311606f05){#GUTJNL2016311606F5}

Given that RSPO3 is a secreted protein, most likely it will act not only in an autocrine but also in a paracrine fashion on adjacent cells expressing the LGR5 and LGR4 receptor. *Lgr4* has been reported to be expressed throughout the entire crypt compartment, present on crypt base columnar cells, Paneth cells and transient amplifying cells.[@R4] *Lgr4* in situ hybridisation revealed that Lgr4^+^ cells presented abundantly throughout the entire *Rspo3*-induced lesions, demonstrating the efficient expansion of these cells upon *Rspo3* expression ([figure 5](#GUTJNL2016311606F5){ref-type="fig"}C). This abundance of Lgr4^+^ cells is in contrast to the more sparsely present Lgr5^+^ cells, which were restricted to the lesion bases ([figures 3B](#GUTJNL2016311606F3){ref-type="fig"} and [5](#GUTJNL2016311606F5){ref-type="fig"}C). Importantly, a comparable distribution pattern of LGR4^+^ and LGR5^+^ cells was observed in xenografts of *RSPO3*-fusion-positive human colon tumours. In these patient-derived tumours, *LGR5* expression was limited and focal, whereas *LGR4* was expressed abundantly throughout the entire tumours, confirming the expansion of LGR4^+^ cells in the human situation ([figure 5](#GUTJNL2016311606F5){ref-type="fig"}D).

In addition to the cycling stem cells, more quiescent stem cells were recently identified that coexpress *Lgr5* and Paneth cell markers. In contrast to the crypt bottom stem cells, these cells are label-retaining, a feature that also holds true for Paneth cells. Moreover, these quiescent cells which are located at the +4 position serve as Paneth cell precursors and as 'reserve' stem cells, acquiring cycling stem cell capacities under specific circumstances.[@R7] [@R8] To investigate the influence of RSPO3 on these quiescent cells, we performed repetitive bromodeoxyuridine (BrDU) injections, and allowed label retention for 1 week or 2 weeks, which was the maximum we could achieve given the *Rspo3-*induced morbidity. Subsequently, double staining was performed for BrDU and lysozyme, allowing discrimination between non-Paneth and Paneth cell LRCs. Transgenic *Rspo3* expression clearly enhanced the presence of total LRCs, 1 week and 2 weeks following BrDU injections (see online [supplementary figure](#SM1){ref-type="supplementary-material"} S3B and [figure 5](#GUTJNL2016311606F5){ref-type="fig"}E, F respectively). Moreover, among these LRCs, lysozyme-negative LRCs were especially enhanced upon *Rspo3* expression, indicating a relative increase in non-Paneth cell LRCs, or, the presumptive Paneth cell precursors that may acquire stem cell activities.

Together these data indicate that *Rspo3* induces lesions that are only partially derived from Lgr5^+^ cells, though in parallel causes an abundant expansion of Lgr4^+^ cells, label-retaining Paneth cells and their presumptive quiescent precursors.

RSPO3 imposes a crypt-associated gene expression profile {#s2d}
--------------------------------------------------------

RNAseq analysis was performed on jejunum tissue of Lgr5 and Rspo3^inv^ single transgenic control mice and Lgr5;Rspo3 double transgenic animals (n=8 per genotype). Unsupervised clustering on gene expression profiles showed tight clustering of Lgr5;Rspo3 tissues (see online [supplementary figure](#SM1){ref-type="supplementary-material"} S4). Lgr5 and Rspo3^inv^ single transgenic controls clustered together, indicating their similarity and justifying to pool them as controls. We found 587 differentially expressed genes of which 255 were increased and 332 decreased ([figure 6](#GUTJNL2016311606F6){ref-type="fig"}A, filtered p\<0.05 and fold change \>1.5). Gene ontology analysis revealed that most significantly enriched molecular and cellular functions upon *Rspo3* expression were related to cellular growth, proliferation, movement and signalling ([figure 6](#GUTJNL2016311606F6){ref-type="fig"}B). Wnt/β-catenin signalling appeared as the second most significantly upregulated signalling pathway, while an increased expression of phosholipase genes *Pla2g5*, *Pla2g2a*, *Pla2g2f, Pla2g4c* and *Pla2g12a* underlied high ranking of the majority of the other pathways, except for the axonal guidance pathway ([figure 6](#GUTJNL2016311606F6){ref-type="fig"}B and see online [supplementary figure](#SM1){ref-type="supplementary-material"} S5A). Taking a closer look at individual genes involved in cellular proliferation, growth and Wnt/β-catenin signalling in the intestine, we found a broad panel of genes among the upregulated genes. In addition to 12 upregulated Wnt signalling related genes, we observed increased transcripts of crypt stem cell markers *Ascl2*, *Hopx*, *Cdca7*, *Tnfrsf19* and *Msi1* and of Paneth cell associated genes *Lyz1* and *Pla2g2a* ([figure 6](#GUTJNL2016311606F6){ref-type="fig"}C). Also, enhanced *Lgr4* expression was observed, corresponding to the above described expansion of Lgr4^+^ cells. Conversely, differentiation markers of non-crypt cell lineages were downregulated, among which *Sis* and *Muc2*, and most significantly downregulated functions involve metabolism and associated signalling pathways (see online [supplementary figure](#SM1){ref-type="supplementary-material"} S5B--D). These expression data match our findings of abnormal cellular growth and crypt hyperplasia, including expansion of Lgr4^+^, Paneth and stem cells and also indicate significantly increased Wnt/β-catenin signalling.

![*Rspo3* induces a crypt-associated gene expression profile. (A) Heat map of normalised per-sample expression values (2log and n=8 per genotype), including differentially expressed genes upon transgenic *Rspo3* expression (filtered p\<0.05 and fold change \>1.5). (B) Gene ontology analysis showing most significantly enhanced molecular and cellular functions (upper panel) and signalling pathways (lower panel) upon *Rspo3* expression. Grey points indicate the gene ratio per signalling pathway. (C) Wnt pathway and crypt-associated genes enriched upon *Rspo3* expression. (D) Relative RNA expression levels in sorted Lgr5-GFP and Paneth cells of either Lgr5 control or Lgr5;Rspo3 transgenic mice as determined by qPCR. Bars indicate the averages with SDs from three mice per genotype sorted during independent experiments. \*p\<0.05, \*\*p\<0.01, \*\*\*p\<0.001, Student\'s t-test.](gutjnl-2016-311606f06){#GUTJNL2016311606F6}

To assess whether the increased mRNA levels of crypt-associated genes solely reflects the expansion of crypt cells or also concerns differential gene expression at the cellular level, Lgr5-GFP stem cells and Paneth cells were sorted by flow cytometry[@R6] from Lgr5 single transgenic control and Lgr5;Rspo3 double transgenic mice. Expression of Lgr5 and lysozyme being restricted to the sorted Lgr5-GFP and Paneth cell populations, respectively, confirmed correct identity of the sorted cells. Gene expression analysis using quantitative PCR revealed enhanced expression of stem cell markers *Lgr5*, *Ascl2* and *Prom1* in sorted Lgr5^+^ stem cells upon transgenic *Rspo3* expression, and transgenic Paneth cells expressed increased levels of lysozyme. Interestingly, Wnt target genes *Axin*2, *Cd44*, *Lef1* and *Sox9* were upregulated not only in Lgr5^+^ stem cells, but also in Paneth cells, as was the case for *Lgr4* as well. Together these data indicate that RSPO3 promotes the expression of Wnt target genes, stem cell and Paneth cell genes by expanding the population of concerning cells, and additionally by stimulating the expression of these stemness-associated genes at the cellular level.

RSPO3 alters organoid morphology and enables RSPO1-independent growth {#s2e}
---------------------------------------------------------------------

Investigating the growth of intestinal organoids from our Lgr5;Rspo3 transgenic mice, we noticed that shortly after seeding, the vast majority of Lgr5;Rspo3 transgenic organoids typically presented as large cysts, or spheres, as has been described for other Wnt activating culture conditions[@R5] and clearly distinct from the appearance of control organoids ([figure 7](#GUTJNL2016311606F7){ref-type="fig"}A, B). Lgr5;Rspo3 spheres did not maintain this cystic phenotype over time but rather showed crypt budding and differentiation after several days. The crypt regions developing in Lgr5;Rspo3 organoids showed aberrant morphology, with the lumen appearing open and being relatively large ([figure 7](#GUTJNL2016311606F7){ref-type="fig"}A, B and see online [supplementary figure](#SM1){ref-type="supplementary-material"} S6). Furthermore, whereas control organoids rapidly died following depletion of exogenous RSPO1 from the medium, Lgr5;Rspo3 organoids survived and maintained their typical morphological phenotype as observed in the presence of RSPO1 ([figure 7](#GUTJNL2016311606F7){ref-type="fig"}C), indicating the functional replacement of exogenous RSPO1 by the transgenic RSPO3. Robust proliferation capacity of the Lgr5;Rspo3 organoids in the absence of exogenous RSPO1 was confirmed by Ki67 staining ([figure 7](#GUTJNL2016311606F7){ref-type="fig"}D).

![RSPO3 alters organoid morphology and allows RSPO1-independent growth. (A) Organoids grown from control and Lgr5;Rspo3 transgenic mice, 2 (upper) and 5 (lower) days after seeding, showing the increase in spheroid growth, aberrant crypt formation and open lumen upon *Rspo3* expression. (B) Percentage of spheres of total organoids in culture, bars indicate the averages with SDs from minimally three experiments. \*p\<0.05, \*\*p\<0.01, Student\'s t-test. (C) Organoids from control mice disintegrate following the depletion of exogenous RSPO1, whereas Lgr5;Rspo3 organoids survive and show similar phenotype as with exogenous RSPO1. (D) Ki67 staining visualising proliferation absence and presence in control versus Lgr5;Rspo3 organoids, respectively, in the absence of exogenous RSPO1.](gutjnl-2016-311606f07){#GUTJNL2016311606F7}

Mutant *Kras* enhances RSPO3-induced hyperplastic, though not neoplastic growth {#s2f}
-------------------------------------------------------------------------------

All human colon tumours with *RSPO2* or *RSPO3* fusion transcripts harboured a mutation in either *KRAS* or *BRAF.*[@R1] To investigate the relevance of mutant *Kras* in the setting of enhanced RSPO3, we cross-bred our Lgr5;Rspo3 mice with *Kras*^G12V^ mice. F1 hybrid progeny was injected with tamoxifen at 25 days of age, activating Cre and enabling expression of *Rspo3* and of the mutant *Kras* allele. Triple transgenic mice expressing both *Rspo3* and mutant *Kras* (Lgr5;Rspo3;Kras genotype) appeared more morbid than corresponding Lgr5;Rspo3 controls, although survival did not differ significantly between Lgr5;Rspo3;Kras and Lgr5;Rspo3 cohorts (see online [supplementary figure](#SM1){ref-type="supplementary-material"} S7). Lgr5;Kras mice displayed no signs of morbidity and accordingly, microscopic analysis of the intestines revealed no phenotypical alterations ([figure 8](#GUTJNL2016311606F8){ref-type="fig"}A). However, mutant *Kras* activation in combination with transgenic *Rspo3* expression revealed an increase in the severity of the hyperplastic phenotype ([figure 8](#GUTJNL2016311606F8){ref-type="fig"}A), indicating that mutant *Kras* and RSPO3 synergistically stimulate hyperplastic growth. In contrast, tumour numbers were not significantly different between the Lgr5;Rspo3 and Lgr5;Rspo3;Kras cohorts ([figure 8](#GUTJNL2016311606F8){ref-type="fig"}B). Restricted to the Lgr5;Rspo3;Kras cohort, three cases of adenomatosis were observed, in which animals displayed multiple adenomatous lesions throughout the small intestine, merging into one another and hampering exact quantification. Given the reported synergy between mutant *Kras* and mutant *Apc* on Wnt/β-catenin signalling,[@R14] we performed immunohistochemical β-catenin stainings on the intestines of mice expressing transgenic *Rspo3* with and without mutant *Kras* ([figure 8](#GUTJNL2016311606F8){ref-type="fig"}C). Nuclear translocation of β-catenin was hardly observed both in Lgr5;Rspo3 and Lgr5;Rspo3;Kras intestines. Accordingly, qPCR analyses showed that RSPO3 increased the expression of *Axin2, Cd44, Sox9* and *Rnf43*, but coexpression of the mutant *Kras* allele from the *Lgr5-*GFP-Cre^ERT2^ cells did not raise the expression levels any further ([figure 8](#GUTJNL2016311606F8){ref-type="fig"}D). Together these data indicate that in this mouse model, when expressed in Lgr5^+^ cells, mutant *Kras* synergises with RSPO3 in hyperplastic growth, but not in promoting Wnt signalling or tumorigenesis.

![Mutant *Kras* and *Rspo3* synergise in hyperplastic though not neoplastic growth. (A) H&E stainings of small intestine of Lgr5;Kras, Lgr5;Rspo3 and Lgr5;Rspo3;Kras mice, showing augmentation of the hyperplastic phenotype in triple transgenic mice. The right-most panel shows a representative example of adenomatosis as observed in Lgr5;Rspo3;Kras mice exclusively. (B) Number of adenoma (left panel) and adenocarcinoma (right panel) observed in Lgr5;Rspo3 and Lgr5;Rspo3;Kras mice, lines indicating the median. Open triangles represent cases of adenomatosis, where tumour numbers are an estimation of ≥20. (C) β-catenin immunostaining on representative neoplastic lesions in small intestine of Lgr5;Rspo3 and Lgr5;Rspo3;Kras mice. Inserts show that nuclear β-catenin detection is not affected by mutant *Kras*. (D) Relative expression of Wnt target genes in the jejunum (n=8 per genotype). \*\*p\<0.01, \*\*\*p\<0.001, Student\'s t-test.](gutjnl-2016-311606f08){#GUTJNL2016311606F8}

Discussion {#s3}
==========

Recognising the prominent role of *APC* and *CTNNB1* mutations in human colorectal cancer, many mouse studies have investigated the effects of activating the associated Wnt/β-catenin signalling pathway, showing proliferative and tumorigenic phenotypes.[@R12] [@R15] Gene fusions leading to enhanced *RSPO3* expression have been proposed as a possible alternative to these most common *APC* or *CTNNB1* mutation routes in driving intestinal cancer.[@R1] We show that transgenic *Rspo3* expression induces a proliferative phenotype resembling that of other Wnt activating mouse models. Moreover, we provide in vivo evidence that RSPO3 stimulates stem cell and niche compartments and drives rapid intestinal tumorigenesis. In line with reported Wnt/β-catenin promoting activities of R-spondin, transgenic *Rspo3* expression potentiated the Wnt signalling pathway, as was apparent from multiple gene expression analyses and cystic organoid morphology. We demonstrated that RSPO3 enhanced Wnt/β-catenin signalling both in Lgr5^+^ stem cells and Paneth cells. Despite this, we hardly observed nuclear translocation of β-catenin in RSPO3-induced lesions, indicating that the gain in Wnt signalling is relatively low, especially compared with *Apc* mutant mouse models. In this regard, it might be interesting to investigate the involvement of alternative signalling factors, and the collective increase of five phospholipase genes propose these as interesting candidates. Among those, *Pla2g2a* has recently been described as an important regulatory stem cell niche factor.[@R22]

Thus, while RSPO3 raises Wnt/β-catenin signalling to a relatively modest level, it drives tumorigenesis efficiently. Importantly, our data also demonstrate that RSPO3 causes an expansion of Lgr5^+^ stem cells, Paneth cells, Lgr4^+^ cells and LRCs. The capacity to stimulate stem cells and niche cells by promoting their Wnt signalling and causing their expansion likely provides RSPO3 with tumorigenic potential. After all, persistent overstimulation of stem cells and their niche cells provides a solid basis for abnormal, uncontrolled tissue growth. This is supported by the recent finding that anti-RSPO3 treatment of existing RSPO3-fusion-positive tumour xenografts inhibits tumour growth and reduces stem cell marker expression.[@R9] [@R10] We demonstrate that stimulation of stemness by RSPO3 thus goes beyond stimulating the Lgr5^+^ stem cells themselves and includes stimulation of Lgr4^+^ cells, Paneth cells and their presumptive precursors. Besides providing Lgr5^+^ stem cells with a stemness-supporting niche, it is of interest to determine whether these alternative, expanded cell types contribute to RSPO3-driven tumorigenesis as a cell of origin. In this regard, very limited lineage tracing was observed from Lgr5^+^ cells in RSPO3-induced lesions, indicating that the lesions derive from alternative cell types. Supportively, quiescent Paneth cell precursors have been described to acquire cycling stem cell properties upon tissue damage, serving as a reserve stem cell pool, and more differentiated intestinal cell types have been shown to act as tumour initiating cells under specific circumstances.[@R8] [@R19] [@R23]

Taken together, we demonstrate that RSPO3 stimulates Lgr5^+^ stem cells, Lgr4^+^ cells, Paneth cells and their presumptive quiescent precursors by causing their expansion as well as promoting the expression of related genes, including Wnt/β-catenin signalling genes. Considering that R-spondins are secreted proteins, this implies that RSPO3 may potentially influence a broad spectrum of stem cell and niche cell types in patients with colorectal cancer harbouring *RSPO3* fusions. Unfortunately, not much knowledge exists to date about the occurrence and functioning of alternative stem cells, Paneth cells and their precursors in the human colon, besides that part of human colon tumours harbour Paneth cells, and their presence in adenoma is associated with an increased risk for developing additional colonic adenomas.[@R16] [@R24] [@R25] We provide in vivo evidence that RSPO3 stimulates the intestinal stem cell and niche compartments and drives rapid tumorigenesis, proposing RSPO3 as a promising candidate therapy target for patients with colorectal cancer carrying *RSPO3* fusions.

Materials and methods {#s4}
=====================

Generation of Rspo3^inv^ transgenic mouse model {#s4a}
-----------------------------------------------

A detailed description of the generation of the *Rspo3* cassette that allows conditional expression of *Rspo3* after Cre activation, and the generation of the FVB.129P2-Gt(Rosa)26Sor^6(CAG-Rspo3)Nki^/A (MGI:5697338, abbreviated to *Rspo3*^inv^) transgenic founder strain is provided in the online supplementary information. Shortly, the *Rspo3* coding sequence was inserted in antisense orientation between two sets of non-homologous *Lox* sites in a head to head orientation, 3′ to the CAGGS promoter in a *Rosa26* gene targeting cassette.[@R26] The obtained *Rspo3*^inv^ construct ([figure 1](#GUTJNL2016311606F1){ref-type="fig"} and see online [supplementary figure](#SM1){ref-type="supplementary-material"} S1A) was introduced into strain 129 derived IB10 E14ES cells by electroporation and selected embryonic stem (ES) cells were injected into 129/Ola blastocysts. Founder strains were back-crossed for five times to 129/Ola, followed by more than nine generations back-crossing to FVB.

Mouse strains and treatments {#s4b}
----------------------------

All mouse strains were maintained heterozygous. The *Rspo3*^inv^ mice were provided with inducible Cre by cross-breeding with *Lgr5*-GFP-Cre^ERT2^ transgenic mice[@R11] on FVB background. Cre was activated by intraperitoneal tamoxifen injection (200 µL 10 mg/mL in corn oil) of single and double transgenic progeny at the age of 2 months, followed by analysis 1--2 months later, unless mentioned otherwise. BrDU was administered by intraperitoneally injecting 100 µL (10 mg/mL in phosphate-buffered saline (PBS)), six times on two consecutive days, and 2 weeks after tamoxifen. Double transgenic *Lgr5-*GFP-Cre^ERT2^;*Rspo3*^inv^ mice were cross-bred to mTmG mice (back-crossed to FVB),[@R27] Rosa26-LacZ mice,[@R28] and *Kras*^LSL\ G12Vgeo^ mice.[@R29] Progeny was injected with tamoxifen at day 25, followed by analysis within 1--2 months.

Histology and immunohistochemistry {#s4c}
----------------------------------

Intestines were formalin-fixed and paraffin-embedded (FFPE), followed by H&E staining according to routine protocols. Cultured organoids were fixed in 4% PFA and embedded in low-melting agarose prior to paraffin embedding. Immunohistochemistry was performed on consecutive sections using antigen retrievals, antibodies and visualisation as indicated in online [supplementary table](#SM1){ref-type="supplementary-material"} SI. For quantification of BrDU/lysozyme-positive cells, Aperio ImageScope software was used to precisely discriminate single or double staining for each cell. Twenty-five GFP-positive jejunum crypts were counted per mouse, followed by averaging the three experiments. X-gal staining was performed as described in the online supplementary information.

RNA in situ hybridisation {#s4d}
-------------------------

RNA in situ hybridisation was performed using RNAscope 2.0 high definition (HD) Brown for FFPE (Advanced Cell Diagnostics (ACD)) and following manufacturer\'s instructions with minor adjustments. Pretreatment (1) 10 min RT, pretreatment (2) boil 15 min and pretreatment (3) 10 min in 40°C hybridisation oven. Probes Mm Lgr4 318321, Mm Lgr5 312171, Hs LGR4 460551 and Hs LGR5 311021 (ACD) were hybridised 2 hours at 40°C. Sections of xenograft tumours derived from *RSPO3*-fusion-positive human colon tumours were obtained from Crown BioScience.

RNA isolation, cDNA synthesis and expression analysis of whole tissue {#s4e}
---------------------------------------------------------------------

For the purpose of RNA sequencing analysis, RNA was isolated from jejunum tissues using TRIzol reagent (Ambion Life Technologies) followed by purification using the MinElute Cleanup Kit (Qiagen). Illumina TruSeq mRNA libraries were generated using the TruSeq RNA Library Preparation Kit v2 (Illumina) and samples were sequenced 51 bp single-end using the Illumina Hiseq2000 platforms (Illumina). Everything was performed according to routine manufacturer's protocols. Limma\'s Voom was used for normalisation and expression data were analysed using Ingenuity Pathway Analysis.

For RT-PCR and qPCR purposes, RNA was isolated from jejunum tissues using TissueLyser LT (Qiagen) and RNeasy Plus Mini Kit (Qiagen), followed by cDNA generation using Maxima First Strand cDNA Synthesis Kit (Fisher Scientific). RT-PCR was performed using MyTaq Red DNA Polymerase and qPCR using SensiFAST SYBR Hi-ROX Kit (both GCBiotech). Primers are shown in online [supplementary table](#SM1){ref-type="supplementary-material"} SII. Expression levels were normalised using *Actb*.

Crypt isolation, culture and cell preparation for flow cytometric sorting {#s4f}
-------------------------------------------------------------------------

Small intestinal crypts were isolated and cultured as described,[@R6] [@R30] using mice that received Tamoxifen at the age of 25 days. Cultured organoids were dissociated with narrowed Pasteurs\' pipettes, seeded into Matrigel (Corning) and maintained for indicated durations, without or with exogenous RSPO1. RSPO1 was supplemented as 10% conditioned medium, derived from HEK293T cells transfected with an Rspo1 expression vector.[@R31]

For flow cytometric sorting, isolated crypts were incubated with TrypLE (Life Technologies) and 2000 U/mL Dnase (Sigma) 10 min, 37°C. Dissociated cells were passed through a 40 μm strainer and stained 30 min at 4°C with BV421-conjugated-TER119, BV421-conjugated-CD31, BV421-conjugated-CD45 and APC-conjugated CD24 (all BioLegend). Sorting was performed using FACS AriaIII (BD Bioscience) as described previously.[@R6] In short, single viable epithelial cells (DAPI^−^ and lineage^−^) were selected based on CD24, GFP and side scatter (SSC). Paneth cells (CD24^hi^SSC^hi^) and Lgr5-GFP^hi^ stem cells were sorted in three independent runs.

Expression analysis of sorted cells {#s4g}
-----------------------------------

RNA was isolated following the Trizol reagent protocol (Invitrogen), adding 1 µL Glyco-blue (15 mg/mL Ambion). RNA was converted into cDNA using the high capacity RNA-to-cDNA kit (Applied Biosystems) and employed in a preamplification step using the TaqmanPreAmp Master Mix (Applied Biosystems). Quantitative PCR was performed using TaqMan probes and assays (Applied Biosystems). Everything was performed according to manufacturer\'s instructions. Expression levels were corrected for *Actb* expression.
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